DIFFERENTIATING AGENTS AND NONTOXIC THERAPIES

This publication has 42 references indexed in Scilit:

• Antiproliferative Effect of 1 ,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation
  Endocrinology, 1998
• Arachidonic Acid Stimulates Prostate Cancer Cell Growth: Critical Role of 5-Lipoxygenase
  Biochemical and Biophysical Research Communications, 1997
• 1,25-Dihydroxyvitamin D3 and 9-cis-Retinoic Acid Act Synergistically to Inhibit the Growth of LNCaP Prostate Cells and Cause Accumulation of Cells in G1
  Endocrinology, 1997
• Influence of isoflavones in soy protein isolates on development of induced prostate‐related cancers in L‐W rats
  Nutrition and Cancer, 1997
• Increased Phospholipid Fatty Acid Remodeling in Human and Rat Prostatic Adenocarcinoma Tissues
  Journal of Urology, 1996
• The Mechanistic Rationale in Support of Dietary Cancer Prevention
  Preventive Medicine, 1996
• Increased susceptibility of ras‐transformed cells to phenylacetate is associated with inhibition of p21^ras isoprenylation and phenotypic reversion
  International Journal of Cancer, 1995
• Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.
  Journal of Clinical Investigation, 1993
• Suramin inhibits bone resorption and reduces osteoblast number in a neonatal mouse calvarial bone resorption assay
  Endocrinology, 1992
• Suramin binds to platelet‐derived growth factor and inhibits its biological activity
  Journal of Cellular Biochemistry, 1985